News
EVADER™ – stealth mode, next-generation AAV-based gene therapy vectors (published in BioPharma Dealmakers)
Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B and to programs that target retinal cells.
> Read More
Chameleon Presents at Solebury Trout Fall Private Company Showcase 2021
Genine Winslow, CEO and Founder of Chameleon Biosciences, was invited to present at the 8th Annual Virtual Solebury Trout Fall Private Company Showcase. This selective, annual showcase highlights new and emerging biotechs. Ms. Winslow shared exciting preclinical data on Chameleon’s proprietary next generation AAV-based vectors which are designed to overcome the immune response related challenges of current AAV gene therapies. See the slides and more.
> Read More
Chameleon Biosciences at CureDuchenne’s National “FUTURES” Conference
Genine Winslow, CEO and Founder of Chameleon Biosciences will be participating in a panel discussion at the upcoming CureDuchenne’s National “FUTURES” Conference.
> Read MorePress Releases
- April 29, 2022
EIN Presswire, MENAFN
Science News Today: CEO/CFO Interviews Chameleon Biosciences, Inc. Founder CEO, Genine Winslow on how they are Expanding AAV Gene Therapies with EVADER™ - March 9, 2022
AP News, Benzinga, Yahoo! Finance:
Chameleon Biosciences Founder to Speak at Gene Therapy Next Generation Vector Summit 2022 in Boston - Jan 5, 2022
AP News, Big News Network, Digital Journal, Yahoo! Finance:
Chameleon Biosciences Appoints Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, to Board Position
What Others Are Saying...
- May 9, 2022
Cell and Gene Therapy Insights:
Overcoming the immune-related shortfalls of AAV - May 3, 2022
Bay Area INNO:
Chameleon Biosciences is developing a better way to treat rare genetic diseases
- Apr 25, 2022
CEO/CFO Magazine:
Expanding AAV Gene Therapies with EVADER™ - Mar-Apr 2022
Bay Area INNO:
Inno Madness
Apr 20, Apr 14, Apr 6, Mar 30, Mar 29, Mar 1 - Apr 14, 2022
BioSpace:
CureDuchenne is Filling the Therapeutic Pipeline with Next Generation DMD Treatments - Apr 14, 2022
eHealth Radio Network:
The Latest in Gene Therapy with Genine Winslow - Feb 15, 2022
BioSpace:
Chameleon's Cloaking Technology Makes Multi-Dose Gene Therapy a Reality - Feb 2, 2022
Bizwomen: In Her Own Words:
Scientist Genine Winslow - Jan 5, 2022
BioWorld:
Appointments & Advancements
EVADER™ – stealth mode, next-generation AAV-based gene therapy vectors (published in BioPharma Dealmakers)
Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B and to programs that target retinal cells.
> Read More Chameleon Presents at Solebury Trout Fall Private Company Showcase 2021
Genine Winslow, CEO and Founder of Chameleon Biosciences, was invited to present at the 8th Annual Virtual Solebury Trout Fall Private Company Showcase. This selective, annual showcase highlights new and emerging biotechs. Ms. Winslow shared exciting preclinical data on Chameleon’s proprietary next generation AAV-based vectors which are designed to overcome the immune response related challenges of current AAV gene therapies. See the slides and more.
> Read More Chameleon Biosciences at CureDuchenne’s National “FUTURES” Conference
Genine Winslow, CEO and Founder of Chameleon Biosciences will be participating in a panel discussion at the upcoming CureDuchenne’s National “FUTURES” Conference.
> Read More